Impact Factor
4.77
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
9.72
5,062 total citations
h5-index
87
h5 depth signal
Cited share
90.6%
490 of 541
Total citations
5,062
Citation footprint
Metric signal
9.73
External metric anchor
Self-citation
2.0%
103 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
751
China
453
India
400
United Kingdom
346
Germany
181
Citing Fields of Research
Drug Delivery Systems
438
Medical Ethics
387
Oncology
288
Pharmacology & Toxicology
259
Cancer Drugs
247
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
7,781
Articles tracked across the journal lifetime
Indexed publication set
541
490 cited publications
Last 12 months
322
26.8 publications/month
Open access share
38.5%
124 OA publications in the last year
Leading citing country
United States
751 citing publications
Leading citing field
Drug Delivery Systems
438 citing publications
Latest tracked publication
20 October 2026
10 recent records available
Coverage & Indexing History
v7n1,Jan. 1 2002-
v4n1,Jan. 1999-
Active Coverage
Research Focus & Classification
Indexed Subjects
Medical Ethics
AI & Machine Learning
Drug Delivery Systems
Cancer, Autophagy & Apoptosis
Protein Structure & Folding
Immunology
Oncology
Broad Categories
Drug Therapy
Pharmacology
Medical Ethics
Protein Structure & Folding
Drug Delivery Systems
Cancer, Autophagy & Apoptosis
Genetics & Genomics
Immunology
MeSH Descriptors
Drug Design
Technology, Pharmaceutical
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1016/j.drudis.2026.104839
Open DOI
Patient access to cell and gene therapies in Europe: stakeholder perspectives on impeding factors across the medicine lifecycle
02
DOI 10.1016/j.drudis.2026.104837
Open DOI
NR4A2: a next-generation drug target orchestrating dynamic gene regulation and protein interactions
03
DOI 10.1016/j.drudis.2026.104836
Open DOI
AI-integrated iPSC multi-omics: advancing phenotype discovery and drug target identification in rare diseases
04
DOI 10.1016/j.drudis.2026.104834
Open DOI
Advancing a drug-development program is not the same as de-risking it
05
06
DOI 10.1016/j.drudis.2026.104833
Open DOI
The role and mechanism of heat shock proteins in the development of pulmonary arterial hypertension
07
DOI 10.1016/j.drudis.2026.104832
Open DOI
Blockbuster drugs and forecast accuracy: How sponsor type is associated with commercial success of FDA-approved medicines
08
DOI 10.1016/j.drudis.2026.104829
Open DOI
Systematic review of EU and US product labels containing real world data in support of efficacy claims
09
DOI 10.1016/j.drudis.2026.104831
Open DOI
From drug repurposing to antiviral activity expansion: building antiviral maps from multiple viral trees
10
DOI 10.1016/j.drudis.2026.104828
Open DOI
An IQ Consortium cross-industry survey and perspective on AI/ML adoption in translational and ADME sciences
Bibliographical & Catalog Notes
Latest issue consulted: surrogate of Vol. 7, no. 8 (Apr. 15 2002); title from cover.
Also issued online.